Clinical Trial Update: EXTENT: EXtended Tolerability and Efficacy of a Novel Formulation of Oxcarbazepine in a Trial in Partial Epilepsy [Phase 3]

View source ↗

Summary

Phase 3 trial EXTENT evaluating an extended-tolerability and efficacy formulation of oxcarbazepine for partial epilepsy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Partial Epilepsy

Drugs mentioned

• Oxcarbazepine (novel formulation) (oxcarbazepine)

Snippet

Sponsor: Desitin Arzneimittel GmbH | Conditions: Partial Epilepsy | Phase 3 | Status: TERMINATED